Tratamiento con Dexametasona en caso de infección por COVID-19 Informe rápido de evaluación de tecnología sanitaria

Tortosa, Fernando; Balaciano, Giselle; Carrasco, Gabriela; Cháves, Clelia; García, Dario; Montero, Guadalupe; Rucci, Pablo; Sanguine, Veronica.
Rev. argent. salud publica ; 12(Suplemento Covid-19): 1-8, 23 de Julio 2020.
Artículo en Español | LILACS, ARGMSAL, BINACIS, BRISA | ID: biblio-1140653

Documentos relacionados

  1. Tratamiento con dexametasona en caso de infección por COVID-19: informe rápido de evaluación de tecnología sanitaria
  2. Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study.
  3. Delayed dexamethasone treatment at initiation of oxygen supplementation for coronavirus disease 2019 is associated with the exacerbation of clinical condition.
  4. A Comparison of the Efficacy of Adjuvant Parenteral Methylprednisolone and Dexamethasone in Reducing Covid-19 Disease Severity and Mortality among the Moderate to Critical Patients -A Retrospective Study.
  5. Real-world effectiveness of steroids in severe COVID-19: a retrospective cohort study.
  6. Preliminary study regarding the predicted body weight-based dexamethasone therapy in patients with COVID-19 pneumonia.
  7. Stability of dexamethasone sodium phosphate over a 28 day period when added to commercial veterinary wipe and pad products.
  8. Effect of high <i>versus</i> low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial.
  9. Prolonged higher dose methylprednisolone <i>versus</i> conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS).
  10. Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support.